Clinical trials: Endocrine Disorder
Hypertension Associated, Type II Diabetes Mellitus
Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension
The purpose of this study is to evaluate the efficacy and safety of Atenas association in the treatment of type 2 diabetes mellitus and hypertension
- Trial name
- ATENAS (NCT05144360)
- Testing
- Atenas
- Sponsor
- EMS
Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background…
- Trial name
- Eluminate-4 (NCT07662135)
- Testing
- Elecoglipron
- Where
- 186 sites in United States, Bulgaria and 14 more
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
Pancreas Cancer
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients.
- Trial name
- NCT00300950
- Testing
- GI-4000, Gemcitabine
- Where
- 28 sites in United States, India
- Volunteers
- 176 people
- Sponsor
- GlobeImmune
Type 2 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications…
- Trial name
- NCT03338010
- Testing
- LY2963016, Lantus®
- Where
- 32 sites in China
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Hypogonadism, Male
Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men
This is an open-label, multi-center, single arm study evaluating the blood pressure (BP) changes from baseline (Visit 3) to post-treatment (Visit 5) assessed by ambulatory blood pressure monitoring (ABPM) in LPCN 1021 treated…
- Trial name
- NCT03868059
- Testing
- LPCN 1021
- Where
- 16 sites in United States
- Volunteers
- 138 people
- Sponsor
- Lipocine Inc.
Type 1 Diabetes
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia
This study will be conducted in a Clinical Research Center (CRC) setting and recruiting type 1 diabetes that are currently using an insulin pump.
- Trial name
- NCT01919385
- Testing
- Predictive Low Glucose Minimizer
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes
Study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS during 4 week treatment duration
- Trial name
- NCT02183415
- Testing
- BI 1356 BS, low dose, BI 1356 BS, medium dose, BI 1356 BS, high dose
- Volunteers
- 77 people
- Sponsor
- Boehringer Ingelheim
T1D, Type 1 Diabetes (T1D)
Evaluation of a Biopsychosocial System
The goal of this observational study is to evaluate the feasibility of a biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for caregivers of children with type 1 diabetes (T1D).
- Conditions
- T1D, Type 1 Diabetes (T1D), Type 1 Diabetes
- Trial name
- NCT07440108
- Testing
- Use of Biopsychosocial Sensing System
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Diabetes Mellitus Type 2
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone.
- Trial name
- NCT01516476
- Testing
- RO6807952, liraglutide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 2
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of…
- Trial name
- NCT02906917
- Testing
- Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
- Where
- 71 sites in United States, Algeria and 5 more
- Volunteers
- 532 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Non-Insulin-Dependent, Dyslipidemia
Safety Study of BMS-816336 in Healthy Male Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics following single oral doses of BMS-816336 in healthy male subjects.
- Trial name
- NCT00979368
- Testing
- BMS-816336
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus
SmartAdjust 2.0 System With Type 1 and Type 2 Diabetes
This study will evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals aged 2-70 years with type 1 or type 2 diabetes.
- Trial name
- NCT06547918
- Testing
- Omnipod 5 SA2.0 System
- Where
- 2 sites in New Zealand
- Volunteers
- 48 people
- Sponsor
- Insulet Corporation
Diabetes, Diabetes Mellitus, Type 2
The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the pharmacodynamic (effect) and pharmacokinetic (exposure of drug) properties of NN1250 (insulin degludec, IDeg) in subjects…
- Trial name
- NCT01043510
- Testing
- insulin degludec, insulin detemir
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Novo Nordisk A/S
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Obesity, Overweight
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07215559
- Testing
- Macupatide, Eloralintide
- Where
- 42 sites in United States, Argentina and 2 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone
The purpose of this study is to evaluate the safety and efficacy of long-term use of pioglitazone/glimepiride combination tablets (Sonias Combination Tablets LD) in patients with type 2 diabetes mellitus who respond poorly to…
- Trial name
- NCT02098746
- Testing
- Pioglitazone/glimepiride
- Volunteers
- 294 people
- Sponsor
- Takeda
Diabetes Type 1
Glycemic Control and Quality of Life Evolution for Patients With T1D Using the myLoop Powered by CamAPS FX System in Combination With FreeStyle Libre 3 / 3 Plus Sensors in France
The goal of this observational study is to learn how glucose control changes over one year in people with type 1 diabetes who use the myLoop with CamAPS FX and Freestyle Libre 3 or FreeStyle Libre 3 Plus during usual care in…
- Trial name
- NCT07835685
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 220 people
- Sponsor
- mylife Diabetes Care AG
Type 1 Diabetes
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm…
- Trial name
- STAR1 (NCT00211510)
- Testing
- Paradigm 722 sensor augmented pump, Paradigm 715 insulin pump
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Medtronic MiniMed, Inc.
Secondary Hyperparathyroidism, Hemodialysis
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT01341782
- Testing
- paricalcitol, maxacalcitol
- Where
- 45 sites in Japan
- Volunteers
- 255 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.